Abstract | OBJECTIVE: METHODS: In this retrospective study we included patients with FIGO 2018 stage IB-IIB cervical cancer. Treatment consisted of 9 weeks' neoadjuvant paclitaxel and carboplatin ( paclitaxel 60 mg/m2, carboplatin AUC 2.7; both weekly) and bevacizumab (15 mg/kg every 3 weeks). The radiologic response rate was analyzed using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. The definition of optimal pathological response was complete disappearance of tumor (complete response, pCR) or residual disease with less than 3 mm stromal invasion (pPR1). Suboptimal pathologic response (pPR2) was defined as persistent residual disease with more than 3 mm stromal invasion. RESULTS: A total of 30 patients were included. Six patients had FIGO 2018 stage IB1-IB2 (20%), one had stage IB3 (3%), five had stage IIA (17%), and 18 had stage IIB (60%). After completing the neoadjuvant chemotherapy, all patients showed a RECIST response (seven (23%) complete response; 23 (77%) partial response). Six patients (20%) were judged to be still inoperable. After radical hysterectomy, optimal pathological response was observed in 11 patients (38%) (pCR in nine patients (29%) and pPR1 in two patients (8%)). Six patients (20%) received postoperative adjuvant chemoradiotherapy. Hematological toxicity was similar to neoadjuvant weekly paclitaxel and carboplatin, as we reported earlier. Grade IV proteinuria or hypertension was not observed and no administration of bevacizumab was delayed or dose-reduced. CONCLUSION:
|
Authors | Charlotte Maene, Rawand Rokan Salihi, Els Van Nieuwenhuysen, Sileny N Han, Nicole Concin, Ignace Vergote |
Journal | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
(Int J Gynecol Cancer)
Vol. 31
Issue 6
Pg. 824-828
(06 2021)
ISSN: 1525-1438 [Electronic] England |
PMID | 33858952
(Publication Type: Journal Article)
|
Copyright | © IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ. |
Chemical References |
- Bevacizumab
- Carboplatin
- Paclitaxel
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology, therapeutic use)
- Bevacizumab
(pharmacology, therapeutic use)
- Carboplatin
(pharmacology, therapeutic use)
- Female
- Humans
- Middle Aged
- Neoadjuvant Therapy
(methods)
- Neoplasm Staging
- Paclitaxel
(pharmacology, therapeutic use)
- Retrospective Studies
- Uterine Cervical Neoplasms
(drug therapy)
|